Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study.
Int Immunopharmacol
; 90: 107261, 2021 Jan.
Article
in English
| MEDLINE | ID: covidwho-957149
ABSTRACT
BACKGROUND:
There is still no specific treatment strategies for COVID-19 other than supportive management.DESIGN:
A prospective case-control study determined by admittance to the hospital based on bed availability.PARTICIPANTS:
Eighteen patients with COVID-19 infection (laboratory confirmed) severe pneumonia admitted to hospital between 20th March and 19th April 2020. Patients admitted to the hospital during the study period were assigned to different beds based on bed availability. Depending on the bed the patient was admitted, the treatment was ozone autohemotherapy or standard treatment. Patients in the case group received ozonated blood twice daily starting on the day of admission for a median of four days. Each treatment involved administration of 200 mL autologous whole blood enriched with 200 mL of oxygen-ozone mixture with a 40 µg/mL ozone concentration. MAINOUTCOMES:
The primary outcome was time from hospital admission to clinical improvement.RESULTS:
Nine patients (50%) received ozonated autohemotherapy beginning on the day of admission. Ozonated autohemotherapy was associated with shorter time to clinical improvement (median [IQR]), 7 days [6-10] vs 28 days [8-31], p = 0.04) and better outcomes at 14-days (88.8% vs 33.3%, p = 0.01). In risk-adjusted analyses, ozonated autohemotherapy was associated with a shorter mean time to clinical improvement (-11.3 days, p = 0.04, 95% CI -22.25 to -0.42).CONCLUSION:
Ozonated autohemotherapy was associated with a significantly shorter time to clinical improvement in this prospective case-control study. Given the small sample size and study design, these results require evaluation in larger randomized controlled trials. CLINICAL TRIAL REGISTRATION NUMBER NCT04444531.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Ozone
/
Blood Transfusion, Autologous
/
SARS-CoV-2
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Int Immunopharmacol
Journal subject:
Allergy and Immunology
/
Pharmacology
Year:
2021
Document Type:
Article
Affiliation country:
J.intimp.2020.107261
Similar
MEDLINE
...
LILACS
LIS